Clinical momentum Celcuity is a clinical-stage, publicly traded biotechnology company advancing a potential first-in-class PI3K/AKT/mTOR pathway inhibitor (gedatolisib) with Phase 3 programs in HR+/HER2- ABC and ongoing combination trials in metastatic castration-resistant prostate cancer, indicating strong near-term follow-on engagement opportunities with investors and research stakeholders.

Lead asset commercial potential The sNDA submission for REVTORPYK (gedatolisib) in PIK3CA-mutant HR+/HER2- breast cancer suggests imminent regulatory and commercial activity, presenting sales prospects around access discussions, payer strategies, and KOL engagement for a potential first-in-class therapy.

Recent investor activity Active participation in multiple investor conferences and a notable increase in institutional stake indicate heightened capital market interest and potential collaboration or licensing conversations with financial partners and strategic investors.

Strong cash runway A robust cash position reported at approximately $754 million provides funding visibility into 2029, enabling continued clinical development, potential expansion of trials, and preparedness for commercial launch activities, which can attract partnerships with CROs, distributors, and manufacturing allies.

Expansion-ready infrastructure With a mid-market headcount and a technology stack including iCIMS, Tableau, Drupal, and BambooHR, Celcuity demonstrates scalable operations and a platform-friendly environment for potential enterprise software, clinical data collaboration, and vendor partnerships to optimize trials and commercialization.